Comparison of metrizamide and iohexol for cisternal myelographic examination of dogs.
A double-blind study, using metrizamide, iohexol, or Ringer's solution (control) as cisternal myelographic agents, was performed on 25 dogs. Before myelographic examination was done, each dog was subjected to physical, clinical pathologic, and neurologic examinations, as well as examinations by electroencephalography and computerized tomography. These were repeated 24 hours after completion of the myelographic examination. The group of dogs given metrizamide (group II) had a significantly greater occurrence of seizure activity (6 of 10) than did the control dogs (group I; 0 of 5) or dogs given iohexol (group III; 0 of 10; P less than 0.003). In group II, the CSF microprotein concentration was significantly greater 24 hours after myelography was done than were the values in groups I and III (P less than 0.003). Myelograms of the group II dogs (metrizamide) and group III dogs (iohexol) had similar diagnostic qualities. At 24 hours after myelographic examination was done, computerized tomography scan revealed that each dog given metrizamide and iohexol had myelographic contrast material in the brain and cervical spinal cord parenchyma. Seemingly, iohexol has good diagnostic quality, but is less epileptogenic than metrizamide when used in cervical myelographic examinations of dogs.
D000818:Animals; D001921:Brain / Q000000981:diagnostic imaging; D002986:Clinical Trials as Topic; D004285:Dogs; D004311:Double-Blind Method; D005260:Female; D007463:Iodobenzoates; D007472:Iohexol; D008297:Male; D008793:Metrizamide / Q000009:adverse effects; D009192:Myelography / Q000379:methods / Q000662:veterinary*; D013116:Spinal Cord / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D008793:Metrizamide